Core Viewpoint - The rise of GLP-1 receptor agonists presents a transformative opportunity in obesity treatment, but a comprehensive approach is necessary to effectively combat the obesity epidemic [2][5][7]. Group 1: Obesity as a Public Health Issue - Obesity is described as a "pandemic" public health issue affecting over 1 billion people globally, with cases increasing in nearly every country [5]. - In 2019, non-communicable diseases related to obesity caused 5 million deaths [5]. - By 2030, global costs associated with obesity are projected to reach $3 trillion [5]. Group 2: GLP-1 Receptor Agonists - The popularity of GLP-1 therapies, particularly in obesity treatment, has surged, with market forecasts estimating the obesity sector could reach $100 billion to $160 billion in the next decade [8]. - The market is currently dominated by Novo Nordisk, with its brands Ozempic and Wegovy, and Eli Lilly, which sells tirzepatide under the names Mounjaro and Zepbound [8]. - Other large and small biopharmaceutical companies are actively investing in this area, aiming to capitalize on the lucrative weight loss trend [8]. Group 3: Recommendations from WHO - WHO officials emphasize that drug treatment alone is insufficient to address the obesity crisis, advocating for a holistic approach that includes prevention and management services that are accessible, affordable, and sustainable [7]. - The current focus on providing interventions only for severely obese individuals or those with related comorbidities is deemed inadequate [7]. - WHO is developing guidelines for the use of GLP-1 therapies in adult obesity patients, with expected publication in July 2025 [7].